{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T05:15:42Z","timestamp":1737868542232,"version":"3.33.0"},"reference-count":41,"publisher":"Japanese Urological Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2024,1,20]]},"DOI":"10.5980\/jpnjurol.115.11","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T22:12:23Z","timestamp":1737324743000},"page":"11-20","source":"Crossref","is-referenced-by-count":0,"title":["UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES","\u5358\u4e00\u65bd\u8a2d\u306b\u304a\u3051\u308b\u9ad8\u816b\u760d\u91cf\u8ee2\u79fb\u6027\u53bb\u52e2\u611f\u53d7\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308bupfront\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u5316\u5b66\u7642\u6cd5\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u306e\u691c\u8a0e"],"prefix":"10.5980","volume":"115","author":[{"given":"Kenichi","family":"Hata","sequence":"first","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Kawaharada","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Enei","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Sakanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hisakane","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital"},{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","unstructured":"1)  ganjoho.jp\/public\/qa_links\/report\/statistics\/2022_jp.html."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lim J, Onozawa M, Saad M, Ong TA, Malek R and Akaza H: Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high- and middle-income Asian countries. Cancer Sci, 112, 2071-2080, 2021.","DOI":"10.1111\/cas.14889"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata K, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H and Eto M: Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci, 112, 1524-1533, 2021.","DOI":"10.1111\/cas.14722"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Grcia JA and DiPaola RS: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373, 737-746, 2015.","DOI":"10.1056\/NEJMoa1503747"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle A, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O&apos;Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J and Parmar MK: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387, 1163-1177, 2016.","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland R, Theodore C, Deplanque G, Ferrero JM, Pouessel D, MMourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G and Soulie M: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncol, 14, 149-158, 2013.","DOI":"10.1016\/S1470-2045(12)70560-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A, Porre PD, Kheoh T, Park YC, Todd MB and Chi KN: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med, 377, 352-360, 2017.","DOI":"10.1056\/NEJMoa1704174"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR and Sweeney CJ: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med, 381, 121-131, 2019.","DOI":"10.1056\/NEJMoa1903835"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L and Stenzl A: ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol, 37, 2974-2986, 2019.","DOI":"10.1200\/JCO.19.00799"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juarez SA, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S and Chowdhury S: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med, 381, 13-24, 2019.","DOI":"10.1056\/NEJMoa1903307"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bublery GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A and Hussain M: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol, 26, 1148-1159, 2008.","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hata K, Tanaka M, Takahashi K and Kimura T: Rupture of liver metastasis in high-volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy. IJU Case Rep, 5 (6), 451-454, 2022.","DOI":"10.1002\/iju5.12512"},{"key":"13","unstructured":"13)  https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pd."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I and Bossi A: Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet, 399, 1695-1707, 2022.","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Motesa-Pino A, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Mendez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I and Tombal B: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med, 386, 1132-1142, 2022.","DOI":"10.1056\/NEJMoa2119115"},{"key":"16","unstructured":"16) Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D&apos;Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA and Freedman-Cass DA: NCCN Guidelines<sup>\u00ae<\/sup> Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw, 20, 1288-1298, 2022."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Yanagisawa T, Kimura T, Mori K, Suzuki H, Sano T, Otsuka T, Iwamoto Y, Fukuokaya W, Miyajima K, Enei Y, Sakanaka K, Matsukawa A, Onuma H, Obayashi K, Tsuzuki S, Hata K, Shimomura T, Miki J and Egawa S: Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. Prostate, 82, 3-12, 2022.","DOI":"10.1002\/pros.24243"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ozaki K, Hatakeyama S, Narita S, Hata K, Yanagisawa T, Tanaka T, Togashi K, Hamaya T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Kimura T, Habuchi T and Ohyama C: Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. World J Urol, 41, 67-75, 2022.","DOI":"10.1007\/s00345-022-04237-3"},{"key":"19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/pros.24404","volume":"82","author":"Y Miura","year":"2018","unstructured":"19) Miura Y, Hatakeyama S, Narita S, Kimura T, Hata K, Yanagisawa T, Tanaka T, Ishii N, Kawamura S, Hoshi S, Ishidoya S, Mitsuzuka K, Ito A, Tsuchiya N, Egawa S, Habuchi T and Ohyama C: Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer; A multicenter retrospective study. Prostate, 82, 1304-1312, 2018.","journal-title":"The Prostate","ISSN":"https:\/\/id.crossref.org\/issn\/0270-4137","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P, Verbeke S, Villeirs G, Man KD, Rottey S, Decaestecker K and Lumen N: Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol, 36, 158.e13-158.e20, 2018.","DOI":"10.1016\/j.urolonc.2017.12.009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kamiya N, Akakura K, Suzuki H, Isshiki S, Komiya A, Ueda T and Ito H: Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol, 44, 309-314, 2003.","DOI":"10.1016\/S0302-2838(03)00303-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Muoio B, Pascale M and Roggero E: The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature. Int J Biol Markers, 33, 10-21, 2018.","DOI":"10.5301\/ijbm.5000286"},{"key":"23","unstructured":"23) \u5f13\u5834 \u899a, \u671d\u5009\u5bff\u4e45, \u5ca1\u7530\u5b9c\u4e4b, \u4f50\u85e4\u5143\u5b5d, \u4efb \u5e79\u592b, \u8fbb\u7551\u6b63\u96c4: \u30a8\u30c8\u30dd\u30b7\u30c9, \u30ab\u30eb\u30dc\u30d7\u30e9\u30c1\u30f3\u7642\u6cd5\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u524d\u7acb\u817a\u5c0f\u7d30\u80de\u764c\u306e2\u4f8b. \u6ccc\u7d00, 62, 639-645, 2016."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Okamura S, Fujiwara Y and Nagata K: Multiple osteolytic bone and lung metastases from prostate cancer including small cell carcinoma with marked increases in CEA and Pro-GRP. Urol Case Rep, 24, 100883, 2019.","DOI":"10.1016\/j.eucr.2019.100883"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kimura T, Koike Y, Aikawa K, Kimura S, Mori K, Sasaki H, Miki K, Watanabe K, Saito K and Egawa S: Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer. Int J Urol, 26, 980-984, 2019.","DOI":"10.1111\/iju.14077"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C, Collinson FJ, Coleman RE, James N, Francis R, Reid DM and McCloskey W: Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol, 25, 100311, 2020.","DOI":"10.1016\/j.jbo.2020.100311"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AW, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraaborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O&apos;Sulivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB and James ND: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol, 29, 1235-1248, 2018.","DOI":"10.1093\/annonc\/mdy072"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S and Habuchi T: Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel. Int J Clin Oncol, 27, 1477-1486, 2022.","DOI":"10.1007\/s10147-022-02203-y"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano Y, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF and Kimura T: Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. Prostate, 83, 563-571, 2023.","DOI":"10.1002\/pros.24488"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Tombal B: What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer, 47, 79-88, 2011.","DOI":"10.1016\/S0959-8049(11)70163-0"},{"key":"31","first-page":"1","author":"AB Weiner","year":"2023","unstructured":"31) Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Chua MLK, Sweeney CJ and Schaeffer EM: A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer, 1-10, 2023.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32) Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Enei Y, Atsuta M, Mori K, Obayashi K, Yoshihara K, Kondo Y, Oguchi T, Sadakane I, Habuchi T, Ohyama C, Shariat SF and Egawa S: Does castration status affect docetaxel-related adverse events?: Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. Prostate, 82, 1322-1330, 2022.","DOI":"10.1002\/pros.24406"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Isaksson J, Green H, Papantoniou D, Pettersson L, Anden M, Rosell J, Avall-Lundqvist E and Elander NO: Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol, 12, 1009-1022, 2021.","DOI":"10.5306\/wjco.v12.i11.1009"},{"key":"34","unstructured":"34)  https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Rush HL, Murphy L, Morgans AK, Clarke NW, Cook AD, Attard G, Macnair A, Deamaley D, Parker CC, Russell JM, Gillessen S, Matheson D, Millman R, Brawley CD, Pugh C, Tanguay JS, Jones RJ, Wagstaff J, Rudman S, O&apos;Sullivan JM, Gale J, Birtle A, Protheroe A, Gray E, Perna C, Tolan S, McPhail N, Malik Z, Vengalil S, Fackrell D, Hoskin P, Sydes MR, Chowdhury S, Gillbert DC, Parmar MKB, James N and Langley RE: Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. Journal of clinical oncology. J Clin Oncol, 40, 825-836, 2022.","DOI":"10.1200\/JCO.21.00728"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Ozaki K, Hatakeyama S, Narita S, Hata K, Yanagisawa T, Tanaka T, Togashi K, Hamaya T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Kimura T, Habuchi T and Ohyama C: Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. World J Urol, 41, 67-75, 2022.","DOI":"10.1007\/s00345-022-04237-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Pelloux-Prayer R, Schiele P, Oudard S, Gravis G, Kleinclauss F, Crehange G, Hennequin C, Morgans AK, Geoffrois L, Limat S, Thiery-Vuillemin A and Nerich V: Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer, 19, e326-e333, 2021.","DOI":"10.1016\/j.clgc.2021.03.022"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Suzuki H, Shin T, Fukasawa S, Hashine K, Kitani S, Ohtake N, Shibayama K, Tran N, Mundle S, Fizazi K and Matsubara N: Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Jpn J Clin Oncol, 50, 810-820, 2020.","DOI":"10.1093\/jjco\/hyaa030"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatakeyama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J and Chi KN: Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study. Int J Urol, 28, 280-287, 2021.","DOI":"10.1111\/iju.14447"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, Matsumoto H, Yokomizo A, Armstrong A, Rosbrook B, Sugg J, Baron B, Chen L, Kunieda F and Stenzl A: Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. Int J Urol, 28, 765-773, 2021.","DOI":"10.1111\/iju.14568"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Tsaur I, Heidegger I, van den Bergh RCN, Bektic J, Borgmann H, Foti S, Hunting JCB, Kretschmer A, Ploussard G, Tilki D, Gandaglia G and Dotzauer R: Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment. Eur Urol focus, 7, 1308-1315, 2021.","DOI":"10.1016\/j.euf.2020.06.018"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/1\/115_11\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:33:48Z","timestamp":1737779628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/1\/115_11\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.115.11","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"type":"print","value":"0021-5287"},{"type":"electronic","value":"1884-7110"}],"subject":[],"published":{"date-parts":[[2024,1,20]]}}}